Nogo Receptor Binding Protein

Abstract

The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.

1 - 57 . (canceled) 
     
     
         58 . A method for identifying an oligodendrocyte in a tissue sample, the method comprising contacting the tissue sample with an anti-Sp35 antibody or an Sp35-binding fragment thereof and an anti-O4 oligodendrocyte marker antibody or an O4-binding fragment thereof, wherein a cell that specifically binds both the anti-Sp35 antibody or Sp35-binding fragment thereof and the anti-O4 antibody or O4-binding fragment thereof is identified as an oligodendrocyte. 
     
     
         59 . The method of  claim 58 , wherein the tissue sample is a spinal cord sample. 
     
     
         60 . The method of  claim 58 , wherein the tissue sample is a primary granular neuron culture. 
     
     
         61 . The method of  claim 58 , wherein the tissue sample is a frontal cortex sample. 
     
     
         62 . The method of  claim 58 , wherein the tissue sample is a posterior cortex sample. 
     
     
         63 . The method of  claim 58 , wherein the tissue sample is an entorhinal cortex sample. 
     
     
         64 . The method of  claim 58 , wherein the tissue sample is a hippocampus sample. 
     
     
         65 . The method of  claim 58 , wherein the tissue sample is an olfactory bulb sample. 
     
     
         66 . The method of  claim 58 , wherein the tissue sample is selected from the group consisting of a striatum sample, a thalamus sample, a cerebellum sample, a midbrain sample, a pons sample, and a medulla sample. 
     
     
         67 . A method for identifying a neuron in a tissue sample, the method comprising contacting the tissue sample with an anti-Sp35 antibody or an Sp35-binding fragment thereof and an anti-βIII tubulin neuronal marker antibody or an βIII tubulin-binding fragment thereof, wherein a cell that specifically binds both the anti-Sp35 antibody or Sp35-binding fragment thereof and the anti-βIII tubulin antibody or βIII tubulin-binding fragment thereof is identified a neuron. 
     
     
         68 . The method of  claim 67 , wherein the tissue sample is a spinal cord sample. 
     
     
         69 . The method of  claim 67 , wherein the tissue sample is a primary granular neuron culture. 
     
     
         70 . The method of  claim 67 , wherein the tissue sample is a frontal cortex sample. 
     
     
         71 . The method of  claim 67 , wherein the tissue sample is a posterior cortex sample. 
     
     
         72 . The method of  claim 67 , wherein the tissue sample is an entorhinal cortex sample. 
     
     
         73 . The method of  claim 67 , wherein the tissue sample is a hippocampus sample. 
     
     
         74 . The method of  claim 67 , wherein the tissue sample is an olfactory bulb sample. 
     
     
         75 . The method of  claim 67 , wherein the tissue sample is selected from the group consisting of a striatum sample, a thalamus sample, a cerebellum sample, a midbrain sample, a pons sample, and a medulla sample. 
     
     
         76 . A method for inhibiting the homotypic interaction of Sp35 or modulating Sp35 interaction with NgR1, the method comprising contacting Sp35 with an oligopeptide of any one of SEQ ID NOs. 10-13. 
     
     
         77 . The method of  claim 76 , wherein the method is for inhibiting the homotypic interaction of Sp35.